BR112022026580A2 - Composições e métodos para induzir uma resposta imune contra coronavírus - Google Patents
Composições e métodos para induzir uma resposta imune contra coronavírusInfo
- Publication number
- BR112022026580A2 BR112022026580A2 BR112022026580A BR112022026580A BR112022026580A2 BR 112022026580 A2 BR112022026580 A2 BR 112022026580A2 BR 112022026580 A BR112022026580 A BR 112022026580A BR 112022026580 A BR112022026580 A BR 112022026580A BR 112022026580 A2 BR112022026580 A2 BR 112022026580A2
- Authority
- BR
- Brazil
- Prior art keywords
- coronavirus
- immune response
- methods
- induce
- compositions
- Prior art date
Links
- 241000711573 Coronaviridae Species 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 108700002099 Coronavirus Nucleocapsid Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044773P | 2020-06-26 | 2020-06-26 | |
| US202063064836P | 2020-08-12 | 2020-08-12 | |
| US202063124200P | 2020-12-11 | 2020-12-11 | |
| US202163145200P | 2021-02-03 | 2021-02-03 | |
| PCT/US2021/039134 WO2021263131A1 (en) | 2020-06-26 | 2021-06-25 | Compositions and methods for inducing an immune response against coronavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026580A2 true BR112022026580A2 (pt) | 2023-01-24 |
Family
ID=79281915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026580A BR112022026580A2 (pt) | 2020-06-26 | 2021-06-25 | Composições e métodos para induzir uma resposta imune contra coronavírus |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230263882A1 (https=) |
| EP (1) | EP4171574A4 (https=) |
| JP (1) | JP2023532290A (https=) |
| KR (1) | KR20230044404A (https=) |
| AU (1) | AU2021294342A1 (https=) |
| BR (1) | BR112022026580A2 (https=) |
| CA (1) | CA3183735A1 (https=) |
| MX (1) | MX2023000041A (https=) |
| WO (1) | WO2021263131A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI884296B (zh) * | 2020-08-11 | 2025-05-21 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
| CA3170743A1 (en) * | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
| WO2023114570A1 (en) * | 2021-12-19 | 2023-06-22 | Massachusetts Institute Of Technology | Compositions and methods for long-lasting germinal center responses to a priming immunization |
| WO2023159081A2 (en) * | 2022-02-15 | 2023-08-24 | Ohio State Innovation Foundation | Nanotechnology based intranasal vaccine for covid-19 |
| CN114752631B (zh) * | 2022-06-15 | 2022-09-02 | 中国人民解放军军事科学院军事医学研究院 | Rna及包含其的新型冠状病毒疫苗和制备方法 |
| WO2024226775A2 (en) * | 2023-04-26 | 2024-10-31 | Elicio Therapeutics, Inc. | Compositions containing polynucleotide and polypeptide amphiphiles and methods of use thereof |
| WO2025240477A1 (en) * | 2024-05-17 | 2025-11-20 | The Regents Of The University Of California | Methods and materials for enhancing delivery of nucleic acid to cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1629104A4 (en) * | 2003-06-04 | 2006-11-02 | Bioleaders Corp | CELL SURFACE EXPRESSION VECTOR OF SARS VIRUS ANTIGEN AND TRANSFORMED MICROORGANISMS |
| WO2006009011A1 (ja) * | 2004-07-15 | 2006-01-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター |
| JP6375289B2 (ja) * | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| JP6487850B2 (ja) * | 2013-11-29 | 2019-03-20 | テルモ株式会社 | アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法 |
| DK3758712T3 (da) * | 2018-03-02 | 2025-08-04 | Elicio Therapeutics Inc | Cpg-amfifiler og anvendelser deraf |
| JP7438604B2 (ja) * | 2020-02-07 | 2024-02-27 | モデルナティエックス インコーポレイテッド | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
-
2021
- 2021-06-25 AU AU2021294342A patent/AU2021294342A1/en not_active Abandoned
- 2021-06-25 CA CA3183735A patent/CA3183735A1/en active Pending
- 2021-06-25 JP JP2022580180A patent/JP2023532290A/ja active Pending
- 2021-06-25 MX MX2023000041A patent/MX2023000041A/es unknown
- 2021-06-25 EP EP21829804.0A patent/EP4171574A4/en active Pending
- 2021-06-25 US US18/012,343 patent/US20230263882A1/en active Pending
- 2021-06-25 BR BR112022026580A patent/BR112022026580A2/pt not_active Application Discontinuation
- 2021-06-25 KR KR1020237002322A patent/KR20230044404A/ko active Pending
- 2021-06-25 WO PCT/US2021/039134 patent/WO2021263131A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183735A1 (en) | 2021-12-30 |
| EP4171574A1 (en) | 2023-05-03 |
| JP2023532290A (ja) | 2023-07-27 |
| AU2021294342A1 (en) | 2023-02-23 |
| MX2023000041A (es) | 2023-03-10 |
| EP4171574A4 (en) | 2024-10-23 |
| US20230263882A1 (en) | 2023-08-24 |
| KR20230044404A (ko) | 2023-04-04 |
| WO2021263131A1 (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
| UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
| BR112022014884A2 (pt) | Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave | |
| BR112022019781A2 (pt) | Vacina para o coronavírus | |
| BR112022015628A2 (pt) | Vacina de sars-cov-2 | |
| CL2021000636A1 (es) | Vacuna contra el virus de la peste porcina africana | |
| BR112022015764A2 (pt) | Construções de ácido nucleico, vetores, vírus do sarampo, composições imunogênicas, processos para recuperar o vírus do sarampo, moléculas de ácido nucleico, polipeptídeos, proteínas recombinantes, usos in vitro de um antígeno, métodos para tratar ou prevenir uma infecção e para induzir uma resposta imune protetora | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| BRPI0707300B8 (pt) | vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| BR112021026439A2 (pt) | Vacina para febre suína africana | |
| AR068507A1 (es) | Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza | |
| BRPI0519705A2 (pt) | composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo | |
| WO2023094713A3 (en) | Coronavirus vaccine | |
| CO2021014778A2 (es) | Subunidad s1 modificada de la proteína de espícula de coronavirus | |
| BR112022016507A2 (pt) | Vacinas contra o coronavírus e métodos de uso | |
| BR112022016580A2 (pt) | Composições e métodos para induzir uma resposta imune | |
| WO2021202734A3 (en) | Universal influenza vaccine using nucleoside-modifield mrna | |
| MX2022012647A (es) | Composiciones que comprenden tres proteinas de fusion de ospa para uso medico. | |
| BR0012919A (pt) | Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv | |
| WO2023147092A3 (en) | Coronavirus vaccine | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| BR112023005043A2 (pt) | Vacina contra covid-19 à base de piv5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |